PPP1R15A — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL29447252	1.00	1/20
SCHEMBL30872248	1.00	1/20
Hydrochloric Acid (SCHEMBL5703102)	0.97	1/20
Acetic Acid (SCHEMBL29736263)	0.82	1/20
SCHEMBL15884162	0.74	1/20
SCHEMBL29445212	0.74	1/20
Guanabenz (SCHEMBL15390)	0.66	1/20
Guanabenz (SCHEMBL219392)	0.66	1/20
Hydrochloric Acid (SCHEMBL5703211)	0.63	1/20
SCHEMBL534016	0.59	1/20
SCHEMBL534017	0.59	1/20
SCHEMBL2161103	0.59	1/20
SCHEMBL6847216	0.59	1/20
SCHEMBL30275282	0.59	1/20
SCHEMBL32680261	0.59	1/20
SCHEMBL5316715	0.57	1/20
SCHEMBL28482894	0.56	1/20
SCHEMBL17560810	0.56	1/20
SCHEMBL17560814	0.56	1/20
Guanabenz (SCHEMBL3054917)	0.55	1/20

Clinical trials — most relevant to PPP1R15A by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Rectal Tacrolimus in the Treatment of Resistant Ulcerative Proctitis	PHASE4	COMPLETED
Treatment With HMG-COA Reductase Inhibitor of Growth and Bone Abnormalities in Children With Noonan Syndrome	PHASE3	COMPLETED
Temsirolimus With or Without Megestrol Acetate and Tamoxifen Citrate in Treating Patients With Advanced, Persistent, or Recurrent Endometrial Cancer	PHASE2	COMPLETED
Sirolimus Treatment in Patients With Autosomal Dominant Polycystic Kidney Disease: Renal Efficacy and Safety	PHASE2	COMPLETED
Everolimus for Children With Recurrent or Progressive Ependymoma	PHASE2	COMPLETED
Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients	PHASE2	COMPLETED
Cixutumumab and Temsirolimus in Treating Patients With Metastatic Prostate Cancer	PHASE1/PHASE2	COMPLETED
Pembrolizumab (MK-3475) in MM Patients With Residual Disease	PHASE2	COMPLETED
Everolimus (RAD001) Therapy for Epilepsy in Patients With Tuberous Sclerosis Complex (TSC)	PHASE1/PHASE2	COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
Evaluating MED2005 & Nitrostat Bioavailability	PHASE1	COMPLETED
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome	PHASE1	COMPLETED
Phase I Study of SC-43 Oral Solution in Subjects With Refractory Solid Tumors	PHASE1	WITHDRAWN
In Vivo Lithium Treatment Effects on Gene Expression Levels in Lymphoblastoid Cell Lines From Human Healthy Subjects	PHASE1	COMPLETED
PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck	PHASE1	COMPLETED
Quantification of GADD34 Expression in RA	nan	COMPLETED
Immune Signature of Palmoplantar Pustulosis	nan	COMPLETED
NGS in Gallbladder Cancer and Response to Treatment	nan	RECRUITING
Lymphoid Tyrosine Phosphatase Gene Polymorphisms in Inflammatory Bowel Disease	nan	UNKNOWN
Role of Sorcin and Annexin A3 in Breast Cancer Patients	nan	UNKNOWN
Studying Biomarkers in Tissue Samples From Young Patients With Acute Myeloid Leukemia Previously Enrolled on Clinical Trial POG-9421	nan	COMPLETED
Studies of the Tumour Suppressor Gene PTEN - Endometrial Cancer	nan	COMPLETED
CircularRNA-microRNA-mRNA Regulatory Axis in IVF	nan	NOT_YET_RECRUITING
Studying Phosphorus Metabolism	nan	COMPLETED
GADD34 and Type I IFN Response Genes in SLE	nan	COMPLETED
Clinical Research for Azacitidine Combined With Low-dose Dasatinib in Maintenance Therapy of Acute Myeloid Leukemia	nan	UNKNOWN
Duality of Lipids: the Athlete's Paradox	nan	COMPLETED
Autophagy in Systemic Lupus Erythematosus	nan	UNKNOWN
SMYD3-Driven Metabolic Rewiring in Colorectal Liver Metastases	nan	NOT_YET_RECRUITING
Analysis of Tumor Tissue and Circulating Genetic Material in the Blood to Obtain Further Insight in the Effectiveness of Everolimus When Combined With Exemestane	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a PPP1R15A binder may also engage these)

Protein	Name	Similarity
Q2KI51	—	0.995	Q2KI51 →
Q60465	—	0.992	Q60465 →
P17564	—	0.992	P17564 →
Q6IN02	—	0.989	Q6IN02 →
Q5TM66	—	0.984	Q5TM66 →
Q8N1P7	—	0.984	Q8N1P7 →
Q767M0	—	0.984	Q767M0 →
Q767L8	—	0.982	Q767L8 →
Q5SV97	—	0.981	Q5SV97 →
Q8BQ30	—	0.981	Q8BQ30 →
A5D7L8	—	0.980	A5D7L8 →
P0C671	—	0.980	P0C671 →
Q7YR40	—	0.980	Q7YR40 →
Q6NYC8	—	0.980	Q6NYC8 →
Q9H7P9	—	0.979	Q9H7P9 →
A5PL33	—	0.979	A5PL33 →
Q5TM68	—	0.979	Q5TM68 →
Q5SWP3	—	0.978	Q5SWP3 →
OGFR	Opioid growth factor receptor	0.978	landscape →
Q9BUA3	—	0.978	Q9BUA3 →
MDC1	Mediator of DNA damage checkpoint protein 1	0.978	landscape →
Q96JP2	—	0.978	Q96JP2 →
Q96L96	—	0.978	Q96L96 →
Q96M43	—	0.978	Q96M43 →
Q149B8	—	0.977	Q149B8 →
Q8NDX1	—	0.977	Q8NDX1 →
Q05AH6	—	0.977	Q05AH6 →
Q7Z591	—	0.976	Q7Z591 →
P58871	—	0.976	P58871 →
Q8N5Q1	—	0.976	Q8N5Q1 →